Johnson & Johnson Cut to "Neutral" at Deutsche Bank; Stock Appears Fully Valued (JNJ)

Johnson & Johnson Cut to “Neutral” at Deutsche Bank; Stock Appears Fully Valued (JNJ)


Diversified healthcare giant Johnson & Johnson (JNJ) on Wednesday caught a big downgrade from analysts at Deutsche Bank.

The firm lowered its rating on JNJ from “Buy” to “Neutral” with a $93 price target, suggesting a small upside to the stock’s Tuesday closing price of $90.40. Deutsche Bank noted that the stock looks fully valued at current levels, given that any major catalysts and better fundamentals have already been priced into the stock.

JNJ shares rose 49 cents, or +0.54%, in early trading Wednesday.

The Bottom Line
Shares of JNJ currently offer a 2.92% dividend yield, based on Tuesday’s closing price of $90.40 and the company’s annualized dividend payout of $2.64 per share.

Johnson & Johnson (JNJ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today